Protocol No
ECOG-EA4181-MCL
Principal Investigator
Timothy Fenske
Phase
II
Summary
This study is being done to answer the following question:
Which combination of cancer drugs most effectively treats MCL?
1. bendamustine, rituximab, and high dose cytarabine (BR/CR)
2. bendamustine, rituximab, high dose cytarabine, and acalabrutinib (BR/CR-A)
3. bendamustine, rituximab and acalabrutinib (BR-A)
Description
Comparison of BR/CR, BR/CR-A, and BR-A in patients under 70 with untreated MCL.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category
ClinicalTrials.gov